Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study.
Abstract: Major drug resistance mutations were detected in samples from 21 (14.6%) of 144 participants; the most frequent mutations were K103N and M184V/I.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, Result: Although these variants still existed at follow-up, the frequencies of the mutations M184VI, K103N and P225H decreased over time, and most of them remained at frequencies of more than 20%.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49), V179D (2.0%, 1/49) and P225H (2.0%, 1/49).
Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.
Abstract: Certain Apolipoprotein B Editing Complex 3-related DRMs including reverse transcriptase gene mutations M184I, E138K, M230I, G190E and protease gene mutations M46I, D30N were enriched in hypermutated sequences but not in intact sequences or plasma sequences.
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 33624081
2021
The Journal of antimicrobial chemotherapy
Abstract: M184I mutation was always associated with a STOP codon, suggesting defective virus.
Abstract: OBJECTIVES: We aimed to deep analyse the detection of M184V/I variants at time of switch and at the time of virological failure (VF).
Abstract: The 48 week estimated probability of remaining free from VF was comparable with or without the M184V/I mutation for dual therapy.
Abstract: The proportion of M184V/I variants was described and the association between the M184V/I mutation at 1% of threshold and VF was explored with logistic regression models.
Increase in HIV-1-transmitted drug resistance among ART-naive youths at the China-Myanmar border during 2009 ~ 2017.
Result: Additional analyses carried out with rilpivirine resistance-associated mutations E138K/M184I or E138K/M184V showed that the combination of amino acid substitutions N348I and T369I had a dominant effect on the RNase H cleavage patterns observed with the PPT-containing 29RNA/28DNA template-primer complex (Figure 5).
Result: While preferential cleavage at the G*A site of the PPT/U3 junction was observed with mutants E138K/M184I and E138K/M184V and the WT HIV-1BH10 RT, the presence of N348I/T369I in any of those sequence contexts al
Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan.
PMID: 32873061
2021
AIDS research and human retroviruses
Abstract: In ART-experienced patients, cohort II, 77.4% (82/106) of viruses contained at least one mutation against PIs, NRTIs, or NNRTIs, with the most common mutations of M184V/I (49.1%; 52/106), K65R (18.9%; 20/106), K103N (23.6%; 25/106), and G190S (22.6%; 24/106).
Transmitted drug resistance to NRTIs and risk of virological failure in naive patients treated with integrase inhibitors.
Abstract: However, the presence of M184V/I independently predicted VF of raltegravir- but not dolutegravir-based therapy when compared with a fully-active backbone [adjusted hazard ratio (aHR) = 3.09, P = 0.035], particularly when associated with other non-thymidine analogue mutations (aHR = 27.62, P = 0.004).
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
PMID: 33200210
2021
The Journal of antimicrobial chemotherapy
Abstract: Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively.
Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.
Abstract: NRTI primary mutations M184 V/I and K65R/E/N were found in 28.8% and 8.9% of subjects respectively, while NNRTI primary mutations K103N/S, G190A, and Y181C were found in 21.0%, 14.6%, and 10.9% of subjects.
Discussion: Similar M184 V/I predominance trends (81.2%) have been reported in Uganda.
Discussion: The fact that 3TC is a backbone for most Kenyan ART-regimens explains this predominance of M184 V/I.
HIV mutation literature information.
PMID: 
2021
Clinical infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT